Immunotherapy for non-small cell lung cancer: Are we on the cusp of a new era?

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

In this editorial, we highlight the exciting advances in immunotherapy for the treatment of non-small cell lung cancer, with nivolumab being the first immunotherapeutic agent to be approved by the US FDA for the treatment of squamous lung cancer and several other promising immune checkpoint inhibitors currently being evaluated in clinical trials. The next step is to understand the mechanisms of resistance and develop rational combinations in an attempt to further improve the responses and survival in lung cancer.

Original languageEnglish
Pages (from-to)871-873
Number of pages3
JournalExpert Review of Clinical Immunology
Volume11
Issue number8
DOIs
StatePublished - Aug 1 2015

Keywords

  • PD-1
  • PDL-1
  • immunotherapy
  • nivolumab
  • non-small cell lung cancer

Fingerprint Dive into the research topics of 'Immunotherapy for non-small cell lung cancer: Are we on the cusp of a new era?'. Together they form a unique fingerprint.

Cite this